Compare CZNC & CUVL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | CZNC | CUVL |
|---|---|---|
| Founded | 1864 | 1999 |
| Country | United States | Australia |
| Employees | N/A | 16 |
| Industry | Major Banks | Miscellaneous |
| Sector | Finance | Miscellaneous |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 465.4M | 374.2M |
| IPO Year | 2009 | N/A |
| Metric | CZNC | CUVL |
|---|---|---|
| Price | $27.61 | $5.00 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | ★ 46.6K | 5.5K |
| Earning Date | 11-03-2026 | 08-27-2026 |
| Dividend Yield | ★ 4.20% | 0.57% |
| EPS Growth | N/A | N/A |
| EPS | ★ 0.81 | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $38.42 | $0.89 |
| Revenue Next Year | $4.97 | $6.69 |
| P/E Ratio | $32.90 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $18.87 | $4.91 |
| 52 Week High | $26.73 | $8.20 |
| Indicator | CZNC | CUVL |
|---|---|---|
| Relative Strength Index (RSI) | 76.41 | 29.90 |
| Support Level | $25.09 | $4.91 |
| Resistance Level | N/A | $6.04 |
| Average True Range (ATR) | 0.62 | 0.15 |
| MACD | 0.22 | -0.02 |
| Stochastic Oscillator | 100.00 | 7.29 |
Citizens & Northern Corp is a community bank operating through its subsidiaries. It provides banking services, including deposit and loan products for personal and commercial customers. The bank also maintains a trust division that provides a wide range of financial services, such as 401(k) plans, retirement planning, estate planning, estate settlements and asset management.
Clinuvel distributes a single product, Scenesse, the only approved treatment for phototoxic reactions specifically associated with a rare genetic disease called erythropoietic protoporphyria. EPP causes extreme pain or burns from brief exposure to light, affecting a patient's quality of life. Scenesse is a patented dissolvable implant, comparable in size with a rice grain, injected underneath the skin roughly every three months for ongoing protection. The implant controls the release of a synthetic drug which promotes the production of more melanin, thereby reducing pain and increasing tolerance for light exposure. The majority of Clinuvel's earnings stem from Europe and the US.